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Background: There is a critical need for improved diagnostic markers for high grade serous epithelial ovarian
cancer (SEOC). MicroRNAs are stable in the circulation and may have utility as biomarkers of malignancy. We
investigated whether levels of serum microRNA could discriminate women with high-grade SEOC from age
matched healthy volunteers.
Methods: To identify microRNA of interest, microRNA expression profiling was performed on 4 SEOC cell lines and
normal human ovarian surface epithelial cells. Total RNA was extracted from 500 μL aliquots of serum collected
from patients with SEOC (n = 28) and age-matched healthy donors (n = 28). Serum microRNA levels were assessed
by quantitative RT-PCR following preamplification.
Results: microRNA (miR)-182, miR-200a, miR-200b and miR-200c were highly overexpressed in the SEOC cell lines
relative to normal human ovarian surface epithelial cells and were assessed in RNA extracted from serum as
candidate biomarkers. miR-103, miR-92a and miR -638 had relatively invariant expression across all ovarian cell lines,
and with small-nucleolar C/D box 48 (RNU48) were assessed in RNA extracted from serum as candidate
endogenous normalizers. No correlation between serum levels and age were observed (age range 30-79 years) for
any of these microRNA or RNU48. Individually, miR-200a, miR-200b and miR-200c normalized to serum volume and
miR-103 were significantly higher in serum of the SEOC cohort (P < 0.05; 0.05; 0.0005 respectively) and in
combination, miR-200b +miR-200c normalized to serum volume and miR-103 was the best predictive classifier of
SEOC (ROC-AUC = 0.784). This predictive model (miR-200b +miR-200c) was further confirmed by leave one out
cross validation (AUC = 0.784).
Conclusions: We identified serum microRNAs able to discriminate patients with high grade SEOC from
age-matched healthy controls. The addition of these microRNAs to current testing regimes may improve diagnosis
for women with SEOC.
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Epithelial ovarian cancer (EOC) is the most lethal
gynecological malignancy, with serous epithelial ovarian
cancer (SEOC) being the most common subtype. Five-year
survival for ovarian cancer is approximately 86% when the
tumor is localized to the ovary; however, the majority of
ovarian cancers are diagnosed at an advanced stage where
5-year survival falls below 25% [1]. This disparity in sur-
vival between early and late stage diagnosis emphasizes the
need to improve early detection of EOC. Currently, diag-
nosis may involve physical examination, transvaginal ultra-
sound and measurement of the serum glycoprotein Cancer
Antigen 125 (CA-125). CA-125 has been reported to de-
tect less than 50% of early stage disease, can be elevated in
other conditions including pregnancy, menstruation and
endometriosis, as well as other cancers and overall is less
reliable than imaging for the diagnosis of ovarian cancer
[2,3]. Other markers include the glycoprotein human epi-
didymis protein 4 (HE4) [4] and OVA1 (Quest Diagnostics,
Madison, NJ, USA), a multivariate index assay comprised
of a panel of 5 markers, Transthyretin, Apolipoprotein A-1,
beta2-Microglobulin, Transferrin and CA-125 [5,6]. Al-
though OVA1 is successful in determining malignancy for
preoperative evaluation (OVA1 was reported to correctly
identify 76% of malignancies missed by CA-125) [5];
decreased specificity and positive predictive value were
reported, resulting in increased benign tumor referral rates
[5,6]. Clearly, there is an opportunity for additional serum
biomarkers to further increase the sensitivity and/or speci-
ficity with which EOC is diagnosed and in so doing, impact
significantly on mortality due to this malignancy.
MicroRNAs (miRNAs) are a class of small (17-22 nu-
cleotide) non-coding RNA molecules that negatively regu-
late gene expression. They display distinct expression
profiles in tumors and are able to differentiate between
cancer and normal tissue, as well as histological subtypes
of ovarian cancer [7-10]. A study in breast cancer reported
a correlation between miRNA expression in tissue and
sera [11]. Circulating miRNAs are stable after multiple
freeze/thaw cycles, RNase A treatment and incubation at
room temperature, with several studies investigating these
as markers of cancer [12-15].
We hypothesized that miRNA over-expressed in SEOC
cell lines may be found in abundance in serum from
women with SEOC compared to age-matched healthy
women. Furthermore, we proposed that miRNAs that are
invariant between SEOC and healthy cohorts may have
utility as endogenous controls to normalize serum miRNA
levels in quantitative PCR (qRT-PCR) analyses.
Methods
Cell lines
The human SEOC cell lines OVCAR-3 [16], PE01 [17],
OV167, OV202 and normal human ovarian surfaceepithelial (OSE(tsT)) cells [18,19] were used in this
study. The sources of these cells, culture conditions
and authentication by short tandem repeat profiling
(The Lady Fairfax CellBank Australia, Westmead, New
South Wales, Australia) are detailed in Additional file 1:
Table S1. All experiments were performed using cells
within 5 passages of those selected for authentication.
RNA Extraction from cell lines
RNA for miRNA microarrays was extracted using Trizol
(Invitrogen, Life Technologies Australia Pty Ltd, Mulgrave
VIC, Australia) and for qRT-PCR using the mirVana
PARIS kit (Ambion, Applied Biosystems, Foster City, CA,
USA), according to each manufacturers’ protocol.
miRNA expression profiling
miRNA expression profiling was performed using 2-color
(Cy-3 versus Cy-5) Exiqon MiRCURY™ Locked Nucleic
Acid arrays (Geneworks Pty Ltd., Thebarton, SA, Australia;
miRBase 8.2 for human; Adelaide Microarray Centre, SA,
Australia). RNA from the cell lines was compared to a
commercial RNA pool (Ambion FirstChoice Human Total
RNA Survey Panel, Applied Biosystems). Triplicate and
duplicate arrays were performed on the OSE(tsT) and
SEOC cell lines respectively, and included a dye-swapped
array for each cell line.
For each array, background correction was performed by
fitting a mixture model of a normal and exponential
distribution where normal distribution captures the non-
expressed probes and exponential distribution the ex-
pressed probes [20]. Loess print-tip normalization was
performed within arrays. Scale normalization was per-
formed between arrays. As each probe was printed as
adjacent duplicate spots, these were expected to be
positively correlated. Therefore, technical replicates were
corrected for using the duplicateCorrelation function to
assess differential expression via Linear Models for Micro-
array data (LIMMA), using the value for the average
correlation to merge data from duplicate spots [21,22].
The raw microarray data have been deposited in NCBI's
Gene Expression Omnibus [23] and are accessible through
GEO Series accession number GSE35951 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE35951). Gene-
Spring GX (v11.0.1, Agilent Technologies) was used for
analysis.
Specimen cohorts and serum collection
Serum from patients with SEOC (n = 28) and age-
matched healthy female volunteers (n = 28) were ob-
tained from the Kolling Institute of Medical Research
Gynecological Tumor Bank (Human ethics protocol
#0812-259 M). Healthy volunteers had no personal or
family history of cancer and had not been hospitalized in
the 6 months prior to collection. The majority of cancer
Table 1 Clinical variables of serous ovarian cancer
patients in the study
Patient Healthy volunteers
(n = 28) (n = 28)
Age (years)


































Yes 2 (breast, Craniopharyngioma)
No 26
Tumour Size
mean 59.3 ± 33.6
min 20
max 140
Table 1 Clinical variables of serous ovarian cancer
patients in the study (Continued)
Degree of cytoreduction
< 2 cm 8




Dead of disease 12
Recurred 12
No evidence of disease 4
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national Federation of Gynecology and Obstetrics
(FIGO) stage 3B/C SEOC; other clinical data are sum-
marized in Table 1.
Total RNA extraction from serum
Total RNA was extracted from 500 μL serum using the
miRVANA PARIS kit according to the manufacturer’s
protocol, except that the acid-chloroform precipitation step
was performed twice[12] and samples were eluted twice
from the column with 105 μL H20 pre-heated to 95°C.
qRT-PCR quantification of miRNA expression in serum
and cell lines
miRNA were quantified by TaqMan miRNA assays (Ap-
plied Biosystems) following reverse transcription (TaqMan
MicroRNA RT Kit, Applied Biosystems) of 10 ng (cell
line) or 40 ng (serum) RNA. To reduce the possible high
intra-assay variance introduced by low abundant miRNA,
a pre-amplification step using TaqMan PreAmp Master
Mix (Applied Biosystems) was performed for all serum
RNA samples with cycling conditions: 2 min at 50°C,
10 min at 95°C followed by 12 rounds of 15 sec at 95°C
and 1 min at 60°C. The resulting pre-amplification pro-
ducts were diluted 1:2.3 and 5 μL used for each 10 μL
miRNA assay. Cycle threshold (CT) values above the de-
terminable range (up to 45) were assigned a CT of 45. All
reactions were performed in triplicate and initially nor-
malized to a calibrator (pool of serum and cell lines RNA)
that was included in every plate.
Small nucleolar RNA C/D box 7 (SNORD7, also re-
ferred to as Z30) was chosen as the endogenous
normalizer for cell line miRNA expression because of its
low variance and moderate abundance across the NCI-
60 cell lines [24]. However, it was not suitable for
normalization of serum miRNA as the levels in serum
were below the limit of detection of our assay (data not
shown). As there are no endogenous miRNA established
as normalizers for serum miRNA from women with or
without SEOC, we assessed a number of candidates and
Figure 1 miRNA microarray profiling of SEOC and OSE(tsT) cell
lines. [A] Heatmap of supervised hierarchical clustering (Euclidean,
Centroid) of miRNAs with at least a 2-fold difference in one or more
SEOC cell lines relative to OSE(tsT) cells; miRNA are listed in
Additional file 1: Table S2. [B] Heatmap showing expression relative
to OSE(tsT) cells (ie OSE(tsT) set to log20) for candidate biomarkers in
SEOC cell lines (miR-200a, b, c, and miR-182) and candidate
endogenous controls for normalization (miR-638, miR-92a and miR-
103). Heatmaps were generated using Genespring software.
Kan et al. BMC Cancer 2012, 12:627 Page 4 of 9
http://www.biomedcentral.com/1471-2407/12/627compared these with serum volume normalization, the lat-
ter currently the most common strategy for normalization
of serum miRNA [25,26].
Statistical analysis
The power of selected miRNA to distinguish between can-
cer and healthy patient groups was assessed by receiver
operating characteristic (ROC) area under the curves
(AUC) analyses using SPSS software v20 (SPSS Australasia
Pty Ltd., Chatswood, NSW, Australia). Leave one out
cross validation was also performed using SPSS. Statistical
significance was determined by the Mann–Whitney U
Test (non-parametric data) or one-way ANOVA (LSD
Post-hoc test). A P-value of ≤ 0.05 was regarded as signifi-
cant. Linear regression analysis was performed to assess
possible correlations between expression of miRNAs and
clinical characteristics using Microsoft Office Excel 2007.
Results
miRNA differentially expressed between SEOC and OSE
(tsT) cell lines
To identify differentially expressed miRNAs in SEOC cell
lines, miRNA expression profiling was performed. Super-
vised hierarchical clustering clearly separated the SEOC
from OSE(tsT) cell lines (Figure 1A, Additional file 1:
Table S2). Candidate biomarkers miR-182, miR-200a, b
and c were selected based on > 2-fold (log2) over-
expression in at least 3 of the 4 SEOC cell lines relative to
OSE(tsT) cells (Figure 1B) and confirmed by qRT-PCR
(P < 0.05, 1-way ANOVA; Figure 2A).
miRNA investigated for uniform expression between
SEOC and OSE(tsT) cell lines
In order to select miRNAs with potential suitability as
endogenous controls for normalization, we generated a
list of 451 miRNAs that were expressed at a constant
level across all SEOC cell lines and OSE(tsT) (test based
on one-way ANOVA with asymptotic P values > 0.05
using Benjamini and Hochberg False Discovery Rate for
multiple testing correction). From this list, miRNA pre-
viously reported to be detected in serum or plasma were
selected for further analysis, specifically, miR-92a, miR-
103 [12,14,27] and miR-638 [28] (Figure 1B). miR-103
had also been reported to have similar expression across
ovarian cancer and normal tissues [29]. Small nucleolar
RNA, C/D box 48 (RNU48) was also assessed as it was
used as a normalizer for miRNA studies in solid
tumours [30] and known to be expressed in serum [12].
qRT-PCR assays were performed on RNA from the cell
lines and confirmed that miR-92a and miR-103 were not
differentially expressed in any of the SEOC cell lines com-
pared to OSE(tsT) cells (P > 0.05; Figure 2B). However,
miR-638 was overexpressed in OVCAR-3 cells, and
RNU48 underexpressed in OV167 and OV202 cellsrelative to OSE(tsT) cells (P < 0.05, ANOVA LSD post-hoc
test; Figure 2B) suggesting that miR-638 and RNU48 may
not be appropriate to use as normalizers.
Levels of candidate endogenous miRNA normalizers in
serum
The levels of each candidate normalizer (miR-103, miR-
92a, miR-638 and RNU48) were assessed in serum RNA
from the SEOC (n = 28) and age-matched healthy donor
(n = 28) cohorts by qRT-PCR assays following a pre-
amplification step. Despite pre-amplification, RNU48
failed to amplify in 36% (20/56) of serum samples and
was eliminated as a candidate normalizer. The remaining
results were assessed following normalization to volume
of serum used for reverse transcription (Figure 3) [26].
No correlations were found between subject age and
miR-103, miR-92a or miR-638 levels (Additional file 1:
Figure S1), and no significant differences between the
Figure 2 Cell line expression of miRNA for investigation. [A] The expression of candidate biomarkers, miR-200a, miR-200b, miR-200c and miR-
182 and [B] the expression of candidate normalizers, miR-103, miR-638, miR-92a and RNU48 in SEOC and OSE(tsT) cell lines by qRT-PCR
normalized to Z30 and plotted as log10 ratios. Results are shown for 3 independent experiments with each experiment performed in triplicate. *P
< 0.05, one-way ANOVA (LSD post-hoc TEST).
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0.768) or miR-92a (P = 0.367; Figure 3). However, for miR-
638, a trend towards higher CTs in the SEOC cohort was
observed (P = 0.063; Figure 3). This finding, in conjunction
with the significant differential expression observed in a
single SEOC cell line (P < 0.05, Figure 2B), led to our rejec-
tion of miR-638 as a candidate normalizer. miR-92a was
also rejected as it had recently been reported to be differ-
entially expressed in serum of women with EOC [27].Figure 3 Candidate miRNA endogenous control levels in serum adjus
(n = 28) and healthy controls (n = 28). P-values determined by the MannFrom these results, miR-103 was chosen as the endogen-
ous normalizer for serum miRNA.Candidate biomarker miRNA expression in serum
We next assessed the miRNA selected as candidate bio-
markers (miR-200a, b, c and miR-182) in serum RNA
from the SEOC and healthy cohorts. Volume adjusted
CTs were normalized to miR-103.ted for volume (ΔCT/L of serum assayed) for SEOC patients
–Whitney U Test.
Figure 4 miR-200a, b and c are significantly elevated and predictors of ovarian cancer in patient serum. [A] Mean expression of miR-182,
miR-200a, miR-200b and miR-200c in cancer and normal serum; volume adjusted values normalized to miR-103 (ΔΔCT/L-1 of serum assayed) +/-
SEM (N = 56). *P < 0.05, ***P < 0.0005, Mann–Whitney U Test [B] ROC curves for miRNA combinations with the highest AUC for volume adjusted
results (vol alone; AUC = 0.705) and volume adjusted results normalized to miR-103 (vol + miR-103; AUC = 0.784).
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vated in the SEOC cohort relative to the healthy group
(Figure 4A), with miR-200c the most significantly differ-
ent between the 2 groups (P < 0.0005). For miR-182 the
levels between the 2 cohorts did not reach significance
(data not shown). No correlations between the 4 miRNA
and subject age were found (Additional file 1: Figure S1).Table 2 ROC-AUC analysis for miR-200a, b and c
miRNA AUC P value Sensitivity (%) Specificity (%)
Normalized by volume and miR-103
miR-200a 0.675 0.025 85.7 35.7
miR-200b 0.722 0.004 85.7 35.7
miR-200c 0.727 0.004 71.4 57.1
miR-200b + c 0.784 <0.001 78.6 46.4
Normalized by volume alone
miR-200a 0.648 0.057 82.1 35.7
miR-200b 0.684 0.018 89.3 32.1
miR-200c 0.702 0.010 75 53.6
miR-200a + b 0.705 0.008 85.7 42.9Correlation of serum miRNA levels with clinical
characteristics
To determine the diagnostic potential of selected miR-
NAs, ROC-AUC curves were constructed for miR-200a, b
and c. A multivariate model that combined miR-200b + c
with normalization by serum volume and miR-103 gave
the highest ROC-AUC for discriminating women with
SEOC from healthy women (AUC= 0.784; Table 2,
Figure 4B). In the absence of a separate validation cohort,
leave one out cross validation was performed for this
model (miR-200b + c) and gave an identical AUC value.
For normalization by serum volume alone, the strongest
model combined miR-200a + b (AUC = 0.705; Table 2,
Figure 4B).
Pre-operative CA-125 values were recorded where
available (Table 1) and compared with miRNA expres-
sion in serum. No associations between any of the 3
miRNAs (miR-200a, b or c) and CA-125 levels were
found (Additional file 1: Table S3). A previous small
study found that sera from 3 patients with low CA-125
levels had elevated miR-92a levels [27]. Therefore, we
compared CA-125 levels with miR-92a expression. No
association was observed (Additional file 1: Table S3).
No significant associations were found between the ex-
pression of any of the miRNA investigated and tumorsize, progression free intervals, survival (Additional
file 1: Table S3) or neoadjuvant therapy (data not shown.)
Discussion
We investigated the levels of 4 miRNA (miR-200a, b, c
and miR-182) in the serum of patients with SEOC (n = 28)
and healthy age-matched volunteers (n = 28) and identi-
fied miR-200c as having the most significantly different
levels between the 2 groups (P < 0.0005, Mann–Whitney
U Test). A multivariate model combining miR-200b and
miR-200c gave the best predictive power to discriminate
SEOC and healthy serum, with a ROC-AUC of 0.784.
In the absence of a second independent set of samples,
the predictive performance of miR-200b +miR-200c was
tested by leave one out cross validation analysis and
resulted in an identical ROC-AUC. While a second set
of independent samples may be preferable for validation
testing, cross validation testing overcomes the recog-
nized difficulty of obtaining additional cohorts.
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miRNA in serum by qRT-PCR is the fact that there are
currently no endogenous miRNA firmly established for
normalization of serum miRNA despite the large number
of studies examining serum miRNA as either biomarkers
or normalizers [26,31]. Of the three smaller studies that
have reported miRNA analysis of serum from patients
with ovarian cancer, only one used qRT-PCR and com-
pared serum from patients with ovarian cancer (mixed
subtypes) with serum from healthy women (Table 3). This
study chose miR-142-3p as the normalizer. However we
found this miRNA to be consistently down-regulated in
the SEOC cell lines relative to OSE(tsT) (Additional file 1:
Table S2). For the current study, miR-103, miR-92a, miR-
638 and RNU48 were assessed as potential endogenous
normalizers and miR-103 chosen as it had low differential
expression between the SEOC and healthy cohorts (P =
0.768). miR-103 has previously been found to be highly in-
variant across a number of cancerous and adjacent normal
tissues including ovarian tissue, and ranked in the top 3 of
16 candidates for use as a normalizer for tissue studies
[29]. It has also been shown to be present in serum and
not differentially expressed between serum samples from
healthy controls and gastric cancer patients [26]. Our find-
ings in SEOC patients and an age-matched healthy cohort
are in agreement with these previous reports.
A highly consistent finding from miRNA profiling of
primary tumor samples of SEOC is over-expression ofTable 3 Serum miRNAs in ovarian cancer
Cohort Subtype Stage RNA origin Platfo
2 cancer unknown IV 1 mL serum microa
9 cancer Mixed, 60% serous I-IV 250uL serum TaqMa
4 normal ——




4 cancer serous IV Matched tumor
and serum (exosomes
from 2.5 mL serum)
microa





10 benign adenoma ——
28 cancer Serous II-IV 500 uL serum TaqMa
Assays
28 normal Age-matched ——miR-200a, b and c (Table 4) [7,8,10]. These 3 miRNA
were also the most highly elevated in the SEOC cell lines
tested in our study. There is a strong correlation be-
tween the levels of these miRNAs in exosomes isolated
from matched serum and tumor cultures from patients
with Stage III SEOC, providing evidence of tumor origin
of these circulating miRNAs (Table 3) [15]. Furthermore,
increased levels of these miRNA were not found in
women with benign ovarian disease (Table 3). The
current study extends this work, showing that miR-200a,
b and c, are positive predictive classifiers of SEOC. It
demonstrates that standard RNA extraction from serum
without the need for the capture and isolation of exo-
somes, is suitable for assessment of tumor-derived
serum miR-200a, b and c in patients with SEOC. In ad-
dition, the age range of the 56 subjects (SEOC patients
and age matched healthy volunteers) tested in this study
spanned almost 5 decades, enabling assessment of sub-
ject age as a possible confounder of serum miRNA
levels. We found no association between subject age and
serum miRNA levels for miR-200a, b, c, (or miR-103,
miR-92a, miR-182, miR-638 or RNU48).
As stated above, there is evidence that the elevated
levels of miR-200a, b and c found in serum from women
with SEOC are derived from the cancerous tissue and
thus may reflect high expression of the miRNA in SEOC
tissue. There is general but not complete concordance
that high expression of at least one member of therm Result Reference




n qRT-PCR array 21 differentially expressed






Increased in cancer versus
normal: miR-21, 92, 93, 29a, 126
[27]
rray (custom) Similar levels between
tumor and serum suggesting
a tumor origin for: miR-21, 141,
200a, 200b, 200c, 203, 205
[15]
rray (custom) Increased in cancer versus benign:
miR-21, 141, 200a, 200b, 200c,




Increased in cancer versus normal:
miR-200a, 200b, 200c
This study
Table 4 Reports of miR-200 in ovarian cancer
miRNA Findings Reference
200a/b/c High expression in ovarian
cancer samples
[7,8,10]
High expression correlated with
decreased progression-free survival
[8]
Decreased in tumors with high
β-tubulin III levels
[33]
200a Increased in 43% of primary
ovarian carcinomas, associated with
high-grade and late-stage tumors
[9]
High expression correlated with
recurrence free survival and,
or, overall survival
[34,35]
Increased tumour growth, targets p38α
and modulates oxidative stress signature
[34]
Sensitized tumors to paclitaxel [34]
200c Targeted TUBB3 for degradation
leading to increased paclitaxel sensitivity
[36]




Decreased adhesion to basement membrane
complex
[36]
Repressed ZEB1, decreased migration and
invasion in HEY cells
[36]
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vival and/or better response to paclitaxel treatment
while paradoxically leading to increased proliferation
(Table 4) [8,33-36]. Improved survival may be due to re-
pression of the miR-200c target, ZEB1 a key transcrip-
tional regulator of epithelial to mesenchymal transition,
and the maintenance of a less invasive and aggressive
epithelial phenotype [36,37]. Improved chemosensitivity
may be due to down regulation of another miR-200c tar-
get, TUBB3/class III beta-tubulin, a component of
microtubules that binds to paclitaxel [33,36]. It may also
be due to miR-200a driving an oxidative stress response
signature thereby increasing sensitivity to paclitaxel in-
duced reactive oxygen species production [34]. With
serum miR-200 levels shown to mirror the levels in the
SEOC tissue [15], these data suggest that serum miR-
200a, b, or c levels may have potential as indicators of
prognosis or response to therapy. In the current study,
the diverse range of chemotherapy administered to
patients precluded correlation of miR-200 family levels
and response to therapy.
Conclusions
We found that miRNA elevated in SEOC cell lines were
also elevated in serum from patients with SEOC valida-
ting this approach to candidate biomarker selection. A
number of these miRNA had previously been repor-
ted to be highly expressed in ovarian cancer tissue,providing further evidence that circulating miRNAs are
shed from the cancer. We propose that specific miRNAs
may have utility as serum biomarkers for SEOC and
identified that a small marker panel combining miR-
200b and c normalized to serum volume and miR-103, is
a positive classifier of SEOC. Testing of a larger cohort
that includes patients with early stage disease is war-
ranted to determine whether the addition of miR-200a,
b or c, to a panel of serum biomarkers may improve
diagnostic sensitivity.
Additional file
Additional file 1: Table S1. Cell lines and cell line typing. Table S2.
Table of differentially expressed miRNAs with at least 2-fold change
(absolute log2 fold change) in at least 1 of 4 cell lines relative to OSE(tsT).
Figure S1. Serum miRNA levels relative to age. Table S3. Pairwise
correlation values for serum miRNA levels and CA-125, tumor size,
progression free interval or overall survival.
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